Osteopontin as a Serologic Marker for Metastatic Uveal Melanoma: Results of a Pilot Study - 21/08/11
, Armin Wolf a, Ulrich Welge-Lüssen a, Arthur Josef Mueller b, Anselm Kampik a, Ulrich Christoph Schaller a
Inquiries to Ingrid Wanke Reiniger, Department of Ophthalmology, Ludwig Maximilians-University, Mathildenstr. 8, 80336 Munich, GermanyRésumé |
Purpose |
To evaluate the protein osteopontin (OPN) as a potential new marker for screening and detection of metastatic uveal melanoma.
Design |
Prospective, clinical study.
Methods |
Twenty-eight plasma samples of 27 patients with uveal melanoma were analyzed, and the OPN plasma levels were quantified. Eight of these patients showed liver metastasis. As a control, we measured OPN levels in eight healthy, age-matched individuals.
Results |
The median plasma concentration of OPN in patients with melanoma without metastasis was 46.78 ng/ml (range, 14.5 to 118.67 ng/ml). In contrast, increased median levels of OPN of 170.72 ng/ml (range, 87.37 to 375.54 ng/ml, P <.001) were seen in eight patients with proven metastatic disease. Healthy patients without uveal melanoma showed a median plasma concentration of OPN of 54.6 ng/ml (range, 38.23 to 71.21 ng/ml).
Conclusion |
The protein OPN seems to be a promising tumor marker for detecting metastatic disease in patients with uveal melanoma.
Le texte complet de cet article est disponible en PDF.
Vol 143 - N° 4
P. 705-707 - avril 2007 Retour au numéro
Article précédent
- Visual Field Defects After Macular Hole Surgery With Indocyanine Green–assisted Internal Limiting Membrane Peeling
- Eiko Tsuiki, Azusa Fujikawa, Noritake Miyamura, Koki Yamada, Kazuaki Mishima, Takashi Kitaoka
- Lipophilic Substances in Intraocular Silicone Oil
- José Carlos Pastor Jimeno, Enrique Rodríguez de la Rúa, Itziar Fernández Martínez, Mª Jesús del Nozal Nalda, Jost B. Jonas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?